Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The abuse liability of ketamine: A scoping review of preclinical and clinical studies
Tuyen T. Le, Isabel Pazos Cordero, Muhammad Youshay Jawad, et al.
Journal of Psychiatric Research (2022) Vol. 151, pp. 476-496
Closed Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

The antidepressant actions of ketamine and its enantiomers
Jenessa N. Johnston, Ioline D. Henter, Carlos A. Zarate
Pharmacology & Therapeutics (2023) Vol. 246, pp. 108431-108431
Open Access | Times Cited: 72
Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study)
Giovanni Martinotti, Antonio Vita, Andrea Fagiolini, et al.
Journal of Affective Disorders (2022) Vol. 319, pp. 646-654
Closed Access | Times Cited: 71
A non-hallucinogenic LSD analog with therapeutic potential for mood disorders
Vern Lewis, Emma M. Bonniwell, Janelle K. Lanham, et al.
Cell Reports (2023) Vol. 42, Iss. 3, pp. 112203-112203
Open Access | Times Cited: 68
Ketamine in neuropsychiatric disorders: an update
Jenessa N. Johnston, Bashkim Kadriu, Christoph Kraus, et al.
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 23-40
Closed Access | Times Cited: 47
Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review
Fabrice Jollant, Romain Colle, Thi Mai Loan Nguyen, et al.
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 33
(R)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological Disorders
Hana Shafique, Julie Demers, Julia Biesiada, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6804-6804
Open Access | Times Cited: 9
Mu Opioid Receptor Activation Mediates (S)-ketamine Reinforcement in Rats: Implications for Abuse Liability
Marjorie R. Levinstein, Meghan L. Carlton, Tommaso Di Ianni, et al.
Biological Psychiatry (2022) Vol. 93, Iss. 12, pp. 1118-1126
Open Access | Times Cited: 33
Use of ketamine for treatment resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada
Carson Chrenek, Bryan Duong, Atul Khullar, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 5
Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network
Pauline Gandolfo, Thomas Soeiro, Élisabeth Jouve, et al.
Fundamental and Clinical Pharmacology (2024) Vol. 38, Iss. 5, pp. 978-987
Open Access | Times Cited: 5
Features of biliary tract diseases in ketamine abusers: a systematic review of case reports
Alireza Teymouri, Hadis Nasoori, Maryamsadat Fakheri, et al.
Journal of Medical Case Reports (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 4
Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychotherapy for methamphetamine use disorder (the KAPPA trial)
Kathryn Fletcher, Nadine Ezard, Krista J. Siefried, et al.
BMJ Open (2025) Vol. 15, Iss. 2, pp. e092504-e092504
Open Access
Temperature and Steric Hindrance-Regulated Selective Synthesis of Ketamine Derivatives and 2-Aryl-Cycloketone-1-Carboxamides via Nucleophilic Substitution and Favorskii Rearrangement
Haojiang Zhai, Penghui Li, Hongshuang Wang, et al.
Organic & Biomolecular Chemistry (2025)
Closed Access
A rare cause of indeterminate biliary stricture
A Filippidis, Rahul Sethia, Manu Nayar, et al.
Endoscopy (2025) Vol. 57, Iss. S 02, pp. S396-S396
Closed Access
Ketamine for mental health - A naturalistic inventory of prescribing practices, safety, and adverse effects
Marta Stuart, Ian Stefanuk, Rebecca Comeau, et al.
PLOS mental health. (2025) Vol. 2, Iss. 4, pp. e0000215-e0000215
Open Access
Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis
Debora de A. Simoes Moreira, Luís Eduardo Gauer, Guilherme Teixeira, et al.
Journal of Affective Disorders (2023) Vol. 330, pp. 227-238
Open Access | Times Cited: 12
Ketamine use in a large global sample: Characteristics, patterns of use and emergency medical treatment
Karen P. Barrios, Dean J. Connolly, Jason Ferris, et al.
Journal of Psychopharmacology (2024)
Open Access | Times Cited: 4
Buprenorphine induced opioid withdrawal syndrome relieved by adjunctive Magnesium: A clinical trial
Mohammad Moshiri, Bita Chaeideh, Mohsen Ebrahimi, et al.
Journal of Substance Use and Addiction Treatment (2024) Vol. 160, pp. 209307-209307
Closed Access | Times Cited: 3
Drug dependence and prescribing ketamine for treatment-resistant depression in Australia and New Zealand
Alistair Carroll, Adam Bayes, Mark Montebello, et al.
Australian & New Zealand Journal of Psychiatry (2024)
Closed Access | Times Cited: 3
The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS)
Angela T.H. Kwan, Joshua D. Rosenblat, Rodrigo B. Mansur, et al.
Journal of Affective Disorders (2024) Vol. 360, pp. 421-426
Closed Access | Times Cited: 3
IV low dose ketamine infusions for treatment resistant depression: Results from a five-year study at a free public clinic in an academic hospital
Gilmar Gutiérrez, Melody J.Y. Kang, Gustavo Vázquez
Psychiatry Research (2024) Vol. 335, pp. 115865-115865
Open Access | Times Cited: 2
IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression
Gilmar Gutiérrez, Jennifer Swainson, Nisha Ravindran, et al.
Psychiatry Research (2024) Vol. 340, pp. 116125-116125
Open Access | Times Cited: 2
Mapping consent practices for outpatient psychiatric use of ketamine
David S. Mathai, Scott M. Lee, Victoria Mora, et al.
Journal of Affective Disorders (2022) Vol. 312, pp. 113-121
Closed Access | Times Cited: 11
Ketamine, an Old–New Drug: Uses and Abuses
Katarina Savić Vujović, Ana Jotić, Branislava Medić, et al.
Pharmaceuticals (2023) Vol. 17, Iss. 1, pp. 16-16
Open Access | Times Cited: 6
A survey of drug liking and cravings in patients using sublingual or intranasal ketamine for treatment resistant depression: A preliminary evaluation of real world addictive potential
Brittany Chubbs, Jay Ching-Chieh Wang, Shaina Archer, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 8
Treatment of ketamine use disorder with combined gabapentin and topiramate: two case reports
Jocelyn Lee, Nitin Chopra, Tianna Costa, et al.
The American Journal of Drug and Alcohol Abuse (2024) Vol. 50, Iss. 3, pp. 426-427
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top